A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study
- 1 January 2004
- journal article
- clinical trial
- Published by Taylor & Francis in Cancer Investigation
- Vol. 22 (3) , 383-388
Abstract
Chemotherapy-induced delayed emesis (DE) can affect up to 50% to 70% of patients receiving moderately and highly emetogenic chemotherapy, although rates are improving. DE most commonly occurs withi...Keywords
This publication has 13 references indexed in Scilit:
- Treatment of Nausea and Emesis During Cancer ChemotherapyJournal of Pain and Symptom Management, 2002
- A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and PainJournal of Pain and Symptom Management, 2002
- The Changeable Nature of Patients' Fears Regarding ChemotherapyJournal of Pain and Symptom Management, 2001
- Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by ChemotherapyNew England Journal of Medicine, 2000
- Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With PharmacokineticsJournal of Clinical Oncology, 1999
- Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Determining the effectiveness of a clinical-practice intervention in improving the control of pain in outpatients with cancerAcademic Medicine, 1997
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996
- Patient-related barriers to management of cancer painPain, 1993